Patent intelligence · US
US 9815850
Compounds, compositions and methods
Compounds, compositions and methods
Patent details — US 9815850
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 14, 2017
- Expiration
- Nov 9, 2037
- Applicant
- DENALI THERAPEUTICS INC.
- Claims
- 41
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P1/16
Quick answer
US 9815850 (Compounds, compositions and methods) is held by DENALI THERAPEUTICS INC.. Status: granted. Granted Nov 14, 2017. Expires Nov 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DENALI THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 41
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P1/16, A61P1/18, A61P11/00
More from DENALI THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12378540
Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
granted -
US 12358928
Compounds, compositions and methods
granted -
US 12358896
LRRK2 inhibitors and methods of making and using thereof
granted -
US 12240902
Anti-TREM2 antibodies and methods of use thereof
granted -
US 12180211
Compounds, compositions and methods
granted -
US 12162948
Methods of engineering transferrin receptor binding polypeptides
granted -
US 12129263
Kinase inhibitors and uses thereof
granted -
US 11999750
Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
granted
Frequently asked questions
What is US patent 9815850?
US 9815850 (Compounds, compositions and methods) is held by DENALI THERAPEUTICS INC.. Status: granted. Granted Nov 14, 2017. Expires Nov 9, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9815850?
DENALI THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 42 pharmaceutical patents for this assignee.
When does US 9815850 expire?
Our index shows an expiration date of Nov 9, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.